About Diagnoplex
Diagnoplex is a company based in Lausanne (Switzerland) founded in 2005 was acquired by Novigenix in February 2015. Diagnoplex has raised $9.68 million across 3 funding rounds from investors including Debiopharm, Novigenix and NeoMed. Diagnoplex operates in a competitive market with competitors including ChromaCode, Geneoscopy, InDex Pharmaceuticals, NeuMoDx and Miroculus, among others.
- Headquarter Lausanne, Switzerland
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$9.68 M (USD)
in 3 rounds
-
Latest Funding Round
$1.38 M (USD), Series A
Jun 07, 2013
-
Investors
Debiopharm
& 3 more
-
Employee Count
Not available
-
Acquired by
Novigenix
(Feb 12, 2015)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Diagnoplex
Diagnoplex has successfully raised a total of $9.68M across 3 strategic funding rounds. The most recent funding activity was a Series A round of $1.38 million completed in June 2013. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Diagnoplex
Diagnoplex has secured backing from 4 investors, including institutional and venture fund investors. Prominent investors backing the company include Debiopharm, Novigenix and NeoMed.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Stage-agnostic life sciences-focused VC firm investing in North America & Europe
|
Locked | Locked | Locked | |
|
Investments are made in innovative life science companies globally.
|
Locked | Locked | Locked | |
|
Biopharmaceutical company focused on oncology, infectious diseases, and orphan drugs
|
Locked | Locked | Locked |
Investor details for Diagnoplex
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Diagnoplex
Investment portfolio details for Diagnoplex
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Diagnoplex
Detailed financials for Diagnoplex
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Diagnoplex Comparisons
Peer comparison for Diagnoplex
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Diagnoplex
Diagnoplex operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as ChromaCode, Geneoscopy, InDex Pharmaceuticals, NeuMoDx and Miroculus, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Digital molecular biology analytics are developed for disease management.
|
|
| Locked | Locked | Locked |
Non-invasive biomarker tests for colorectal cancer are developed.
|
|
| Locked | Locked | Locked |
DNA-based immunomodulatory drugs for ulcerative colitis are developed.
|
|
| Locked | Locked | Locked |
Developer of a platform for low cost molecular testing
|
|
| Locked | Locked | Locked |
MicroRNA profiling platform is developed to detect genes in samples.
|
|
| Locked | Locked | Locked |
Point-of-care molecular diagnostics are enabled by Ultrafast Photonic PCR technology.
|
Detailed competitors of Diagnoplex
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Diagnoplex
Complete news archive for Diagnoplex
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Diagnoplex
Diagnoplex was founded in 2005 and raised its 1st funding round 3 years after it was founded.
Diagnoplex is headquartered in Lausanne, Switzerland. It is registered at Lausanne, Vaud, Switzerland.
Diagnoplex is a funded company, having raised a total of $9.68M across 3 funding rounds to date.
Diagnoplex was founded in 2005 in Lausanne, Switzerland, focusing on biotechnology and molecular diagnostics. A platform technology called single-channel quantitative multiplex reverse transcriptase-polymerase chain reaction was created, enabling simultaneous quantification of up to 60 genes. The Colox test, a non-invasive blood-based assay for early colorectal cancer detection, was introduced and made available through laboratories in Switzerland via a partnership with Unilabs. Acquisition by Novigenix occurred in February 2015.
Diagnoplex's top competitors include ChromaCode, Geneoscopy and NeuMoDx.
Diagnoplex has 4 investors. Key investors include Debiopharm, Novigenix, NeoMed, and Novartis Venture Fund.